CTLA4 and Miyoshi myopathy: Our results are encouraging and support the hypothesis that this CTLA4 polymorphism could be used as a biomarker to predict the outcome of MM and we suggest that genetic variants of CTLA-4 should be used as genetic marker to identify patients with high risk of progression, who may benefit of anti-CTLA-4-based therapy.